Lifshitz Law PLLC Announces an Investigation of Molina Healthcare, Inc. (NYSE:MOH), Hub Group, Inc. (Nasdaq:HUBG), Kyndryl Holdings, Inc. (NYSE:KD), and Hims & Hers Health, Inc. (NYSE:HIMS)

NEW YORK, NY / ACCESS Newswire / February 19, 2026 / Lifshitz Law Firm

Molina Healthcare, Inc. (NYSE:MOH)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information.

According to Molina Healthcare Inc.'s ("Molina" or the "Company") 8-K, filed on February 5, 2026, the Company issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and the Company's full-year 2026 revenue and earnings guidance. As highlighted in the press release, the Company reported: (i) fourth quarter 2025 GAAP loss per diluted share of $3.15 and adjusted loss per diluted share of $2.75 were burdened by approximately $2.00 of unfavorable retroactive revenue items; (ii) GAAP net income for the full year 2025 was $8.92 per diluted share, a decrease of 56% year over year. Adjusted net income for the full year 2025 was $11.03 per diluted share, a decrease of 51% year over year. The fourth quarter and full year 2025 results were burdened by approximately $2.00 per share of unfavorable retroactive premium adjustments attributable to the Company's Medicaid business in California and ongoing medical cost pressure in Medicare and Marketplace; and (iii) full year 2026 earnings guidance with expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.00 per diluted share. The adjusted earnings guidance is burdened by $2.50 per share related to the implementation of a new Medicaid contract and underperformance in the traditional Medicare Advantage Part D product, which the Company will exit for 2027.

According to Joseph Zubretsky, President and Chief Executive Officer of Molina, "We believe that the imbalance between rates and trend marks 2026 as a trough year for Medicaid industry margins. Even at this low point in the cycle, we continue to produce positive pretax margins in Medicaid. We remain optimistic about the future earnings trajectory of the enterprise which includes anticipated rate restoration and future embedded earnings."

On February 6, 2026, the Company's stock price dropped sharply on unusually heavy trading volume.

If you are an MOH investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq by telephone at (516) 493-9780 or e-mail at [email protected].

Hub Group, Inc. (Nasdaq:HUBG)

According to Hub Group Inc.'s ("Hub" or the "Company") 8-K, filed on February 5, 2026, the Company issued a press release reporting announcing certain preliminary results for the full year and fourth quarter ended December 31, 2025. As highlighted in the press release, the Company reported: (i) Full year 2025 ITS Segment operating revenue is expected to be approximately $2.2 billion. Full year 2025 ITS Segment operating revenue reflects a fourth quarter increase of 1% in intermodal volumes with flat revenue per load on a year-over-year basis and an intermodal volume increase of 3% on a sequential basis. Dedicated revenue declined in the fourth quarter due to lost sites from earlier in the year, partially offset by operational discipline and service improvements; and (ii) Full year Logistics Segment operating revenue is expected to be approximately $1.6 billion. Full year 2025 Logistics Segment operating revenue reflects softer fourth quarter demand across business lines partially offset by new business wins. Final mile volume was negatively impacted due to onboarding investments that continued in the fourth quarter. Brokerage volumes in the fourth quarter declined 10% year-over-year with revenue per load down 4% year-over-year.

In addition, the Company's 8-K further detailed that in connection with the preparation of its financial statements for the year ended December 31, 2025, the Company identified an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025. The Audit Committee of the Board of Directors of the Company, following the recommendation of management, concluded that the unaudited consolidated financial statements of the Company included in the Quarterly Reports on Form 10-Q for each of the quarterly periods ended March 31, 2025, June 30, 2025, and September 30, 2025 filed with the SEC on May 9, 2025, August 6, 2025 and November 5, 2025, respectively, were in each case materially misstated due to the aforementioned error and should no longer be relied upon.

On February 6, 2026, the Company's stock price dropped sharply on unusually heavy trading volume.

If you are an HUBG investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq by telephone at (516) 493-9780 or e-mail at [email protected].

Kyndryl Holdings, Inc. (NYSE:KD)

According to Kyndryl Holdings, Inc.'s ("Kyndryl" or the "Company") 8-K, filed on February 9, 2026, the Company issued a press release announcing the results of the Company's operations for the third fiscal quarter ended December 31, 2025. As highlighted in the release, the Company reported: (i) reported pretax income of $91 million, compared to pretax income of $258 million in the prior-year period, in which the Company recorded a significant transaction-related benefit; (ii) net income of $57 million, or $0.25 per diluted share, in the quarter, compared to net income of $215 million, or $0.89 per diluted share, in the prior-year period; and (iii) adjusted net income was $122 million, or $0.52 per diluted share, compared to adjusted net income of $124 million, or $0.51 per diluted share, in the prior-year period.

Additionally, the Company announced leadership changes, specifically, that Harsh Chugh has been named Interim Chief Financial Officer, Mark Ringes has been named Interim General Counsel, and Bhavna Doegar has been named Interim Corporate Controller effective immediately.

On February 9, 2026, the Company's stock price dropped sharply on unusually heavy trading volume.

If you are a KD investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq by telephone at (516) 493-9780 or e-mail at [email protected].

Hims & Hers Health, Inc. (NYSE:HIMS)

On February 5, 2026, Hims & Hers Health, Inc. ("Hims" or the "Company") issued a press release announcing "...an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as [Novo Nordisk's] Wegovy®."

Following this news, on February 6, 2026, the U.S. Food & Drug Administration announced: "its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies - including Hims & Hers and other compounding pharmacies - as similar alternatives to FDA-approved drugs. These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy." Additionally, on February 9, 2026, John F. Kuckelman, Novo Nordisk's Senior Vice President, Group General Counsel of Global Legal, IP and Security, announced Novo Nordisk's lawsuit against the Company for infringing on its semaglutide patent, stating "We've taken legal action to protect the American public and our intellectual property and will continue to work with regulators, law enforcement, and other key stakeholders to ensure patients have access to FDA approved safe and effective medicines."

On February 9, 2026, the Company's stock price dropped sharply on unusually heavy trading volume.

If you are a HIMS investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq by telephone at (516) 493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLLC

Phone: 516-493-9780

Facsimile: 516-280-7376

Email: [email protected]

SOURCE: Lifshitz Law Firm